Gobi Partners became Airwallex's first institutional investor in 2016 due to a lack of support in the Australian company's home market. The GP made a partial exit in a recent Series D round at a valuation of $2.6 billion
New York makes an unexpected reappearance as the preferred IPO destination for Asian companies; the growth-stage tech investment revival continues; KKR lights up lackluster fundraising environment
Coupang’s bumper IPO has underlined the appeal of a Korean e-commerce industry characterized by chaebols playing catch-up and PE and VC investors looking to profit at the margins
Affirma Capital has reached a first close of KRW443 billion ($403 million) on its fifth Korea-focused fund, while simultaneously announcing a $181 million investment in SK Telecom’s mobility business.
Falcon Edge Capital has led a $110 million growth round for India’s OfBusiness, a B2B platform for industrial sector services, at a post-money valuation of $800 million.
Gupshup, an India-based messaging services provider that helps corporate customers execute marketing strategies, has raised $100 million in funding at a valuation of $1.4 billion.
Suzhou Abogen Biosciences, a Chinese mRNA vaccine provider, has raised RMB600 million ($92 million) led by PICC Capital - an investment unit under People’s Insurance Company of China - and state-backed SDIC Venture Capital.
Tiger Global Management has led a $502 million Series E round for ShareChat, which claims to be India’s largest social media platform, at a valuation of $2.1 billion.
Australian graphic design platform Canva has more than doubled its valuation to $15 billion with a new $71 million growth round. It was valued at $3.2 billion 18 months ago.
Prosus Ventures and TPG Growth have co-led a $350 million Series E round for India’s API Holdings, best known as the parent of pharmacy portal PharmEasy.
DST Global and Coatue Management have led a $700 million Series D for China-based online fresh produce delivery business Dingdong Maicai. Existing investors including CMC Group re-upped.
SoftBank Vision Fund 2 has led a $300 million round for Meesho, India’s leading social e-commerce start-up, at a valuation of $2.1 billion.
Trax, a Singapore-headquartered start-up that uses computer vision technology to help retailers link sales to in-store and on-shelf positioning, has secured $640 million in Series E funding led by SoftBank Vision Fund 2 and BlackRock.
L Catterton has invested JPY20 billion ($182 million) in PHC Holdings Corporation, a Japanese healthcare business – formerly known as Panasonic Healthcare – backed by KKR.
Japanese payments start-up Paidy has raised $120 million in Series D funding from JS Capital Management, Soros Capital Management, Tybourne Capital Management, and Wellington Management.
FountainVest Partners and ClearVue Partners have led a $220 million funding round for Plus, a China-based autonomous driving technology developer that specializes in trucks.
Alibaba Group and DST Global have led a $750 million Series D round for Shihuituan, a China-based community group buying platform also known as Nice Tuan.
Two emerging Chinese beverage brands - Genki Forest and Tasogare, which focus on sparkling water and coffee, respectively - have completed new funding rounds.
Matrix Partners China has led a second tranche of Series E funding - worth $90 million - for Yunxuetang, a Chinese online corporate training services provider.
Hetao 101, a Chinese online education platform that provides computer programming courses for children, has raised $200 million in Series C funding led by KKR, Vision Plus Capital, and GL Ventures.
Abu Dhabi-based Gulf Capital has committed $30 million to a plan that will see its global fertility services platform launch 18 clinics in India over the next 12 months.
KKR and Sequoia Capital India have led a $234 million investment in Indian non-banking financial company (NBFC) Five Star Business Finance at a valuation of $1.4 billion.
Dream Sports, operator of India’s largest fantasy sports platform, has raised $400 million in funding led by TCV, D1 Capital Partners and Falcon Edge Capital. The post-deal valuation is nearly $5 billion.
Shanghai-based EpimAb Biotherapeutics has raised $120 million in Series C funding led by CMB International and Korea’s Mirae Asset Financial Group.